Pharmaceutical firm Gilead has admitted paying hundreds of thousands of dollars in illegal kickbacks to US doctors between ...

Gilead Sciences has agreed to pay USD 202 million to settle a whistleblower lawsuit that accused the company of engaging in ...

After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

A disruption in federal funds has jeopardized HIV testing and outreach in Mississippi, and researchers warn of a resurgence ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Gilead Sciences has agreed to pay $202 million to resolve allegations that it violated the Anti-Kickback Statute by using speaker programs to incentivize physicians to prescribe HIV medications.

Gilead is a vast pharmaceutical multinational. With a $175 billion market capitalisation nothing about the company is going to be small. There's a large HIV treatment arm which gives it a base in ...

President Donald Trump, in his first term, promised to end America’s HIV epidemic — and he put the resources of the federal ...

Gilead to Pay $202 Million to Settle DOJ Claims Over Speaker Program Kickbacks - Gilead Sciences, Inc. has agreed to pay $202 ...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ...

Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine. However, Ben Hargreaves finds that the company’s ...